Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
about
Drug-Resistant Epilepsy: Multiple Hypotheses, Few AnswersGene-wide tagging study of the association between KCNT1 polymorphisms and the susceptibility and efficacy of genetic generalized epilepsy in Chinese population.Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian populationAlternative splicing modulates inactivation of type 1 voltage-gated sodium channels by toggling an amino acid in the first S3-S4 linker.Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic PatientsRelationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysisInfluence of the SCN1A IVS5N + 5 G>A Polymorphism on Therapy with Carbamazepine for Epilepsy.Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population.Epilepsy pharmacogenetics.Association of SCN1A gene polymorphism with antiepileptic drug responsiveness in the population of Thrace, Greece.Pharmacogenomics and epilepsy: the road ahead.Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs.Personalized medicine approaches in epilepsy.The pharmacogenomics of epilepsy.Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers.SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study.Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy.SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs.Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients.SCN1A variations and response to multiple antiepileptic drugs.A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy.SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis.Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels.Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han populationA commonSCN1Asplice-site polymorphism modifies the effect of carbamazepine on cortical excitability-A pharmacogenetic transcranial magnetic stimulation study
P2860
Q33875271-7F2DA314-F5AF-4380-8EED-7393D7ACD3BAQ35054372-65F3D3F6-4685-4579-8E53-8FC9E05017B3Q35073509-DDD18CBB-79F0-45F6-A46C-FBAC0E882D73Q35378377-C85B52F2-CFB5-4221-88E3-B603EA48A3FFQ35814413-7FB50B23-A831-470D-AE51-16963A649D56Q35837256-B17E016C-4C4D-4D68-A232-4635D4F752D0Q36281662-0AE87281-5A07-4DE4-B241-B3BC658A2C1CQ37181448-63F1EB5E-5790-41FA-B4C8-B25ABADE5B38Q37399443-72746D38-C3EE-4211-A7C4-16CD91284494Q37486720-796C9AF6-B393-4AE2-8547-5C626510C6A2Q37549339-176122B5-A286-4958-8F8C-A22EA952D698Q37946957-10CF0533-C6BA-4B89-8A36-13CCE33B8AC7Q38181565-28FADC40-B52F-458B-A663-2E8A2DA7CCC8Q38262011-0BC2CC37-3ACB-447C-B0CF-7BD8422D1E74Q38577986-B68EA7A6-A01B-479A-9EC0-9383B154E879Q38803195-7C9CABE6-37C1-457C-AA8C-D122C4F5EF47Q39538104-8FB0FDBC-A925-4B3F-A478-71753D521B72Q41445901-6AB10952-4151-4283-9DC4-2EC86EAE4DE4Q42088430-AB6E7CC5-5512-4C83-A66C-3AD8201C69B7Q42985589-C55C30F2-70F7-4F89-B7A4-D348950A3D87Q43903895-87BCF2D4-C2EE-43C5-8B64-9B8BF66C0E3DQ45016382-31D9727D-C4A1-4429-B1EC-637756FD5EE4Q45171680-9BCF7ABB-8284-4AFC-98F0-CE1D8FC05F55Q47998164-C635EDE5-5C8C-4D10-9513-065B0BE6F84FQ51728400-3E76DBA2-4979-41A5-94F0-2D8AFBE64B3CQ55055431-6B630F43-1166-453B-BB52-16B4A46AF5C2Q57500255-1F815E2A-C9DA-4609-AC45-4AA1C4F0A779Q57927061-BA376553-30A2-4CA2-9892-0BA55E103734
P2860
Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
@ast
Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
@en
type
label
Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
@ast
Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
@en
prefLabel
Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
@ast
Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
@en
P2093
P2860
P1476
Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
@en
P2093
Kazuko Nakagawa
Masaharu Hori
Takateru Ishitsu
Takayuki Seo
Takehiro Nakagawa
Tomohide Abe
P2860
P304
P356
10.1111/J.1365-2125.2008.03203.X
P407
P577
2008-04-11T00:00:00Z